Reports Q4 revenue $36.2M, consensus $36.2M. "We are pleased with our solid performance this quarter and the second half of 2022 which saw improved surgical capacity and predictability in hospitals," commented Karen Zaderej, chairman, CEO, and president of Axogen, Inc. "We believe the combination of an improved hospital operating environment and commercial execution, backed by our high-quality portfolio of clinical data provides a solid foundation for long term, sustainable growth."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXGN:
- Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results
- AxoGen appoints Began as EVP, General Counsel
- Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel
- Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023
- AxoGen management to meet with Jefferies